Cargando…
Targeting shared molecular etiologies to accelerate drug development for rare diseases
Rare diseases affect over 400 million people worldwide and less than 5% of rare diseases have an approved treatment. Fortunately, the number of underlying disease etiologies is far less than the number of diseases, because many rare diseases share a common molecular etiology. Moreover, many of these...
Autores principales: | Zanello, Galliano, Garrido‐Estepa, Macarena, Crespo, Ana, O'Connor, Daniel, Nabbout, Rima, Waters, Christina, Hall, Anthony, Taglialatela, Maurizio, Chan, Chun‐Hung, Pearce, David A, Dooms, Marc, Brooks, Philip John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331571/ https://www.ncbi.nlm.nih.gov/pubmed/37366158 http://dx.doi.org/10.15252/emmm.202217159 |
Ejemplares similares
-
Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients
por: Zanello, Galliano, et al.
Publicado: (2022) -
Infectious Etiologies of Chronic Diseases: Focus on Women
por: O'Connor, Siobhán, et al.
Publicado: (2004) -
Salmonella Surveillance Systems in Swine and Humans in Spain: A Review
por: Martínez-Avilés, Marta, et al.
Publicado: (2019) -
Towards the international interoperability of clinical research networks for rare diseases: recommendations from the IRDiRC Task Force
por: Nabbout, Rima, et al.
Publicado: (2023) -
Infectious Etiologies of Childhood Leukemia: Plausibility and Challenges to Proof
por: O’Connor, Siobhán M., et al.
Publicado: (2007)